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ABSTRACT
PD-L1-blocking antibodies produce signiﬁcant clinical beneﬁt in selected cancer patients by reactivating
functionally-impaired antigen-experienced anticancer T cells. However, the efﬁcacy of current PD-L1-
blocking antibodies is potentially reduced by ‘on-target/off-tumor’ binding to PD-L1 widely expressed on
normal cells. This lack of tumor selectivity may induce a generalized activation of all antigen-experienced
T cells which may explain the frequent occurrence of autoimmune-related adverse events during and after
treatment.
To address these issues, we constructed a bispeciﬁc antibody (bsAb), designated PD-L1xEGFR, to direct
PD-L1-blockade to EGFR-expressing cancer cells and to more selectively reactivate anticancer T cells.
Indeed, the IC50 of PD-L1xEGFR for blocking PD-L1 on EGFRC cancer cells was »140 fold lower compared
to that of the analogous PD-L1-blocking bsAb PD-L1xMock with irrelevant target antigen speciﬁcity.
Importantly, activation status, IFN-g production, and oncolytic activity of anti-CD3xanti-EpCAM-redirected
T cells was enhanced when cocultured with EGFR-expressing carcinoma cells. Similarly, the capacity of PD-
L1xEGFR to promote proliferation and IFN-g production by CMVpp65-directed CD8C effector T cells was
enhanced when cocultured with EGFR-expressing CMVpp65-transfected cancer cells. In contrast, the
clinically-used PD-L1-blocking antibody MEDI4736 (durvalumab) promoted T cell activation indiscriminate
of EGFR expression on cancer cells. Additionally, in mice xenografted with EGFR-expressing cancer cells
111In-PD-L1xEGFR showed a signiﬁcantly higher tumor uptake compared to 111In-PD-L1xMock. In
conclusion, PD-L1xEGFR blocks the PD-1/PD-L1 immune checkpoint in an EGFR-directed manner, thereby
promoting the selective reactivation of anticancer T cells. This novel targeted approach may be useful to





Immune checkpoint protein programmed death-ligand 1 (PD-
L1) normally serves to dampen adoptive immune responses in a
timely and localized manner in order to prevent collateral dam-
age and autoimmunity by limiting antigen-experienced PD-1C/
CD8C T cells to proliferate, produce cytokine and attack cells.1
However, cancer cells misuse PD-L1 for incapacitating antican-
cer PD-1C/CD8C T cells in the tumor microenvironment.2
Indeed, PD-L1 expression by cancer cells was found to be associ-
ated with unfavorable prognosis in various malignancies.3-5 In
this process, cancer cells constitutively express PD-L1 due to
aberrant oncogenic signaling6 or upregulate PD-L1 in response
to IFN-g locally released by activated anticancer T cells.2,7
Blockade of the PD-1/PD-L1 checkpoint using antagonistic
antibodies has produced unprecedented antitumor responses in a
subgroup of immunogenic cancer types. In particular, PD-L1-
blocking antibodies, such as atezolizumab, avelumab, and durvalu-
mab, showed prominent clinical activity in patients with advanced
stage melanoma8-10 and non-small-cell lung carcinoma
(NSCLC).11,12 However, the efﬁcacy of current conventional
monospeciﬁc PD-L1-blocking antibodies is potentially hampered
due to on-target/off-tumor binding to numerous normal cell types
that also express PD-L1. In this respect, binding to PD-L1-express-
ing cells in blood or other tissue may prevent antibody extravasa-
tion and accumulation at the site of the tumor.13,14 Moreover, lack
of tumor-selectivity appears to result in generalized activation of
antigen-experienced T cells, including functionally silenced auto-
reactive T cells. The latter aspect is evidenced by the frequent
occurrence of severe autoimmune-related adverse events during
and after treatment with PD-L1-blocking antibodies.
CONTACT Wijnand Helfrich w.helfrich@umcg.nl Department of Surgery, Laboratory for Translational Surgical Oncology, University Medical Center Groningen,
Hanzeplein 1, 9713 GZ, Groningen, The Netherlands.
#contributed equally.
Supplemental data for this article can be accessed on the publisher’s website.
© 2018 Iris Koopmans, Djoke Hendriks, Douwe F. Samplonius, Robert J. van Ginkel, Sandra Heskamp, Peter J. Wierstra, Edwin Bremer and Wijnand Helfrich. Published with license by Taylor &
Francis
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/),
which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
ONCOIMMUNOLOGY
2018, VOL. 7, NO. 8, e1466016 (11 pages)
https://doi.org/10.1080/2162402X.2018.1466016
To address these issues, we developed a bispeciﬁc antibody
that aims to direct PD-L1-blockade to cancer cells and thereby
reactivate anticancer T cells more selectively. Bispeciﬁc anti-
bodies (BsAbs) are a valuable class of emerging therapeutics
that combine two target functionalities harnessed into one anti-
body-based molecule. As target for our PD-L1-blocking bsAb
we selected the epidermal growth factor receptor (EGFR), a
well-established oncogenic tumor-associated surface antigen
that is overexpressed and/or mutated in various epithelial
malignancies, including colorectal cancer and non-small-cell
lung cancer.15,16 Of note, FDA-approved anti-EGFR antibodies
necitumumab and cetuximab17 inhibit oncogenic EGFR signal-
ing and show clinical efﬁcacy in cancers also responsive to PD-
1/PD-L1 checkpoint inhibition.18
These notions prompted us to devise a targeted strategy
for EGFR-directed blockade of PD-1/PD-L1 interaction. As
far as we are aware, this is the ﬁrst report of a bsAb that
selectively directs PD-L1 blockade to EGFR-overexpressing
cancer cells. This approach may represent an important
step towards enhancing selectivity, efﬁcacy and safety of
PD-1/PD-L1 checkpoint inhibition approaches in EGFR-
overexpressing malignancies.
Results
PD-L1xEGFR simultaneously binds to PD-L1 and EGFR
PD-L1xEGFR dose-dependently bound to CHO.PD-L1 cells
and not to wt CHO cells (Fig. 1A). Moreover, PD-L1xEGFR
dose-dependent bound to A431 cells, whereas PD-L1xMock
only showed minimal binding to A431 cells (Fig. 1B). Binding
levels of PD-L1xEGFR towards a panel of PD-L1C/EGFRC cell
lines closely correlated with the respective expression levels of
EGFR (Suppl. Fig. 2A). In contrast, relative low binding of PD-
L1xEGFR was detected towards a panel of PD-L1C/EGFR¡ cell
lines (Fig. 1C). Further, binding of PD-L1xEGFR to EGFRhigh
A431 cells was strongly inhibited in the presence of excess
amounts of EGFR-blocking mAb 425, whereas excess amounts
of a PD-L1-blocking mAb only partly inhibited binding.
Importantly, binding of PD-L1xEGFR to A431 cells was abro-
gated only in the combined presence of excess amounts of a
PD-L1-blocking mAb and mAb 425 (Fig. 1D), indicating PD-
L1xEGFR selectively and simultaneously binds to PD-L1 and
EGFR. Since EGFR expression levels on cancer cells typically
strongly exceed those of PD-L1, we reason that binding of
bsAb PD-L1xEGFR to EGFRC cancer cells is usually dominated
by its capacity to target EGFR.
PD-L1xEGFR has superior PD-L1-blocking capacity
for PD-L1C/EGFRC cancer cells
PD-L1xEGFR and PD-L1xMock were compared for their
capacity to block PD-L1 on EGFR-expressing cancer cells using
a competitive binding assay. In this assay, the IC50 of PD-
L1xEGFR for inhibiting the binding of a competing APC-
labeled PD-L1 mAb to A431 cells was calculated to be
0.013 mg/ml which was »140 times lower than the IC50 calcu-
lated for PD-L1xMock. Importantly, when EGFR binding to
A431 cells was blocked by pre-incubation with mAb 425, the
IC50 of PD-L1xEGFR increased »50 fold (from 0.013 to
0.549 mg/ml; Fig. 1E). These data indicate that, compared to
PD-L1xMock, PD-L1xEGFR has superior PD-L1-blocking
capacity for PD-L1C/EGFRC cancer cells.
PD-L1xEGFR inhibits EGFR-mediated cancer cell
proliferation
Treatment with PD-L1xEGFR showed similar capacity as mAb
425 (Fig. 2A and B) and cetuximab (data not shown) to inhibit
the proliferation of FaDu and H292 cancer cells. In contrast,
PD-L1xMock and isotype control antibodies did not impact
the proliferation of FaDu or H292 cells.
PD-L1xEGFR blocks PD-1/PD-L1 interaction in an
EGFR-directed manner
In the standard PD-1/PD-L1 Blockade Bioassay, PD-L1xEGFR
and PD-L1xMock showed comparable dose-dependent block-
ade of PD-1/PD-L1 interaction with an IC50 value of »2.5 mg/
ml (Fig. 2C). Of note, in this non-targeted setting the IC50 of
MEDI4736 for blocking PD-1/PD-L1 was 18 times lower than
that of PD-L1xEGFR and PD-L1xMock. Next, the capacity of
PD-L1xEGFR for EGFR-directed PD-1/PD-L1 blockade was
assessed by replacing CHO.PD-L1/CD3 cells in the standard
PD-1/PD-L1 Blockade Bioassay by A431 cells (PD-L1C/
EGFRC/EpCAMC) that were pretreated with a suboptimal
amount of bsAb BIS-1; an EpCAM-directed CD3-agonistic
bsAb.19 In the presence of BIS-1-coated A431 cells, the lucifer-
ase expression by Jurkat.PD1-NFAT-luc cells was effectively
repressed. However, treatment with PD-L1xEGFR resulted in a
dose-dependent increase in luciferase-mediated luminescence
in Jurkat.PD1-NFAT-luc cells (Fig. 2D). Of note, in this EGFR-
directed setting, the capacity of PD-L1xEGFR to release the
PD-1/PD-L1 break on luminescence in Jurkat.PD1-NFAT-luc
cells became comparable to that of MEDI4736. These results
indicate that the PD-L1-blocking activity of PD-L1xEGFR is
markedly lower than that of MEDI4736. However, upon con-
current EGFR-binding PD-L1xEGFR regains potent PD-L1-
blocking activity comparable to that of MEDI4736.
PD-L1xEGFR enhances activity of bsAb-redirected T cells
Recently, it was reported that blockade of PD-1/PD-L1 aug-
ments the killing capacity of BiTE-redirected T cells.20 In our
model system, we used a suboptimal amount of BIS-1 to redi-
rect T cells towards EpCAMC carcinoma cells that was titrated
to induce low levels of apoptosis in FaDu and A431 cancer cells.
In this setting, addition of PD-L1xEGFR resulted in a potent
increase of apoptotic cancer cell death of »35% (Fig. 3A and B)
which was accompanied by a markedly increased production of
IFN-g (Fig. 3C) and upregulation of CD25 expression (Suppl.
Fig. 2B). In contrast, addition of MEDI4736 or PD-L1xMock
only marginally enhanced (»5%) the cytotoxic potential of
BIS-1-redirected T cells. Of note, addition of anti-EGFR mAb
425 appeared to sensitize A431 and FaDu cancer cells to killing
by BIS-1-redirected T cells (18% and 22%, respectively), which
is likely attributable to its capacity to inhibit oncogenic EGFR-
signaling. Addition of PD-L1xEGFR or mAb 425 to T cells that
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were not redirected by BIS-1 resulted in background levels of
apoptosis in FaDu and A431 cells (Fig. 3A and B). Taken
together, this indicates that the capacity of PD-L1xEGFR to
enhance the anticancer activity of BIS-1-redirected T cells is
attributable to its concurrent ability to block both PD-L1 sig-
naling and oncogenic EGFR-signaling.
Next, we evaluated whether PD-L1xEGFR enhances anti-
cancer activity of BIS-1-redirected T cells in an EGFR-directed
manner. To this end, EGFRC and EGFR¡ cancer cells were
brieﬂy incubated with PD-L1xEGFR or control antibodies, after
which unbound antibodies were removed by washing. In this
setting, PD-L1xEGFR potently enhanced the anticancer activity
of BIS-1-redirected T cells towards EGFRC A431 and FaDu
cancer cells, with essentially no enhanced activity towards
EGFR¡ A2058.EpCAM cells (Fig. 3D, E, F). In contrast,
MEDI4736 only marginally enhanced the anticancer activity of
BIS-1-redirected T cells towards cancer cells indiscriminate of
EGFR expression. Taken together, PD-L1xEGFR but not
MEDI4736 speciﬁcally enhances the anticancer activity of BIS-
1-redirected T cells in an EGFR-directed manner.
PD-L1xEGFR enhances activity of antigen-experienced
T cells
Next, we evaluated the capacity of PD-L1xEGFR to enhance the
cytotoxic potential of authentic antigen-experienced T cells. To
this end, CMVpp65-experienced T cells from healthy CMV-
seropositive volunteers were cocultured with A431.pp65 or wt
A431 cancer cells. In this setting, PD-L1xEGFR potently
enhanced the cytotoxic activity of CMVpp65-experienced T
cells towards A431.pp65 and not wt A431 cells. The enhanced
cytotoxic potential of these T cells was corroborated by an
increased cell surface expression of activation markers CD25,
HLA-DR, CD137 and CD107a (Fig. 4A to D and suppl. Fig 3),
and an increased production of IFN-g and granzyme B (Fig. 4E
and F). Of note, expression of CD137 is reported to be
restricted to T cells recently activated through TCR-mediated
signaling and as such here identiﬁed the activation of pp65-
experienced anti-CMV CD8C T cells by PD-L1xEGFR. Simi-
larly, the increased expression of degranulation marker
CD107a is indicative of an increased cytotoxic activity of anti-
gen-experienced T cells.21 Taken together, these results indi-
cated that PD-L1xEGFR enhances the activity of antigen-
experienced T cells.
PD-L1xEGFR induces NK cell-mediated ADCC in EGFRC
cancer cells
PD-L1xEGFR contains a fully functional human IgG1 domain
and thus may trigger NK cell-mediated ADCC towards EGFR-
expressing cancer cells. Indeed, NK cell-mediated ADCC
towards FaDu and LNCaP cells was enhanced by PD-L1xEGFR
Figure 1. PD-L1xEGFR selectively and simultaneously binds to PD-L1 and EGFR (A) Dose-dependent binding of PD-L1xEGFR to CHO.PD-L1 vs. parental CHO cells. (B) Dose-
dependent binding of PD-L1xEGFR vs. PD-L1xMock to PD-L1C/EGFRC A431 cells. (C) Binding of PD-L1xEGFR vs. PD-L1xMock (5 mg/ml) to a series of PD-L1C/EGFRC and
PD-L1C/EGFR¡ cell lines. (D) Binding of PD-L1xEGFR (1 mg/ml) to A431 cells in the presence or absence of excess PD-L1-blocking antibody and/or EGFR-blocking mAb
425. (E) Competitive binding assay in which anti-PD-L1-APC competed with increasing doses (0.01–50 mg/ml) of PD-L1xEGFR (black line) or PD-L1xMock (grey line) for
binding to A431 cells. Where indicated, A431 cells were pre-treated with excess amounts of mAb 425 (50 mg/ml) (red line) or isotype control IgG2a (green line) for
15 min. All binding experiments were analyzed by ﬂow cytometry. Statistical analysis in D was performed using One-way ANOVA followed by a Bonferroni post-hoc test
(p < 0.05,  p < 0.01,  p < 0.001, ns not signiﬁcant).
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or cetuximab, but not by PD-L1xMock or mAb 425 (Fig. 5A to
C). Thus, PD-L1xEGFR combines EGFR-directed immune
checkpoint blockade with ADCC towards EGFRC cancer cells.
Enhanced tumor uptake of 111In-PD-L1xEGFR in EGFRC
tumor xenografted mice
Tumor uptake of PD-L1xEGFR and PD-L1xMock was compared
in vivo using nude mice xenografted with EGFRC SK-BR-3 or
A431 cancer cells. PD-L1xEGFR and PD-L1xMock were labeled
with 111In at a speciﬁc activity of 50 kBq/pmol with an efﬁciency
of 95%. In vitro cell binding analysis demonstrated that radiolabel-
ing of 111In-PD-L1xEGFR did not compromise its binding capac-
ity for PD-L1 or EGFR (Fig. 6A and B). Blood clearance of 111In-
PD-L1xEGFR and 111In-PD-L1xMock in non-tumor-bearing
mice indicated comparable biological half-lives of »24 h and 30
h, respectively (data not shown). Importantly, in SK-BR-3 and
A431 tumor-bearing mice, 111In-PD-L1xEGFR showed a signiﬁ-
cantly higher tumor uptake compared to 111In-PD-L1xMock
(p D 0.001). Tumor uptake in A431 tumor-bearing mice for
111In-PD-L1xEGFR and 111In-PD-L1xMock were 19% and 13%
ID/g, respectively. Tumor uptake in EGFRC SK-BR-3 tumor-bear-
ing mice for 111In-PD-L1xEGFR and 111In-PD-L1xMock were
15% and 7% ID/g, respectively (Fig 6C and suppl. Fig 4). In both
tumor models the tumor-to-blood-ratio for 111In-PD-L1xEGFR
was notably higher compared to 111In-PD-L1xMock (p D 0.001)
(Fig. 6D). These data indicate that accumulation of PD-L1xEGFR
in EGFRC tumors is higher compared to PD-L1xMock.
Discussion
The efﬁcacy of current PD-L1-blocking antibodies is poten-
tially hampered by ‘on-target/off-tumor’ binding to normal
cells expressing PD-L1. This lack of tumor-selective binding
may reduce tumor accretion of PD-1/PD-L1-blocking antibo-
dies. Moreover, this may also induce an indiscriminate reacti-
vation of antigen-experienced T cells, including functionally
silenced yet potentially deleterious autoreactive T cells, leading
to severe autoimmune-related adverse events during and after
treatment.8,12,22
Therefore, we developed a novel bsAb-based approach that
aims to more selectively direct PD-L1 blockade to cancer cells.
BsAbs allow to selectively target, modulate and interconnect
biologic activities of otherwise separately acting cell surface
receptors and ligands on the same cell or between neighboring
cells in a predesigned manner.
Figure 2. PD-L1xEGFR induces tumor growth inhibition and blocks the PD-1/PD-L1 interaction (A) Representative light microscopy images of PD-L1C/EGFRC FaDu cells
after 5 days treatment with 5 mg/ml PD-L1xEGFR, PD-L1xMock, mAb 425 or isotype control as indicated. (B) Cell viability of FaDu and H292 cells after treatment as in A
was determined by MTS and expressed as percentage of medium control. Graphs represent mean§ SD. (C) Blockade of the PD-1/PD-L1 interaction analyzed using a com-
mercially available PD-1/PD-L1 Blockade Bioassay (Promega). CHO.PD-L1/CD3 cells and Jurkat.PD-1-NFAT-Luc cells were treated with an increasing dose (0.01–10 mg/ml)
of PD-L1xEGFR, PD-L1xMock, MEDI4736 or isotype control. NFAT-RE-mediated luciferase activity was quantiﬁed using a plate reader and expressed as fold increase com-
pared to medium control. (D) Similar to C, mixed cultures of A431 cells and Jurkat.PD1-NFAT-luc cells were treated with increasing doses (0.01–10 mg/ml) of indicated
antibodies in the presence of 75 ng/ml BIS-1. Statistical analysis in B was performed using One-way ANOVA followed by a Bonferroni post-hoc test ( p < 0.05,  p <
0.01,  p < 0.001, ns not signiﬁcant).
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We selected EGFR as a particularly suitable target antigen for
this approach. Recently, it was reported that EGFR activation by
either EGF, exon-19 deletions or L858R mutation promotes PD-
L1 expression by cancer cells.6,23 EGFR overexpression is known
to promote immune evasion of malignant cells by inhibiting the
activation of signal transducer and activator of transcription 1
(STAT1) while promoting that of STAT3.24,25 Several EGFR-tar-
geted agents are currently available that inhibit oncogenic EGFR
signaling, including small-molecule EGFR kinase inhibitors (geﬁ-
tinib, erlotinib and osimertinib) and antagonistic antibodies
(necitumumab, nimotuzumab and cetuximab). Indeed, our
results show that geﬁtinib and erlotinib sensitize cancer cells to
apoptosis induction by BIS-1-redirected T cell (Suppl. Fig. 2C
and D). Moreover, our results suggest that the capacity of PD-
L1xEGFR to enhance the anticancer activity of BIS-1-redirected
T cells is attributable to its concurrent ability to block both PD-
L1 signaling and oncogenic EGFR-signaling.
PD-L1xEGFR is constructed in a so-called bispeciﬁc taFv-Fc
format,26 a class of symmetric tetravalent bispeciﬁc molecules
that can be equipped with an Fc domain of choice. Our data
demonstrate that the capacity of PD-L1xEGFR to simultaneously
bind to PD-L1 and EGFR results in an signiﬁcantly enhanced
overall binding strength (avidity) for PD-L1C/EGFRC cancer
cells. Of note, EGFR expression by carcinoma cells usually
exceeds expression of PD-L1. Indeed, in mice with EGFRC xeno-
grafts the tumor accumulation of 111In-PD-L1xEGFR was signiﬁ-
cantly higher than that of control 111In-PD-L1xMock. Obviously,
more detailed ﬁt-for-purpose evaluation of our approach needs
to be performed e.g. in patient-derived xenograft (PDX) models
using EGFR-transgenic and humanized NSG mice, but such
is clearly beyond the scope of the current report.
Interestingly, in a bioassay for PD-1/PD-L1 blockade PD-
L1xEGFR showed reduced capacity to block PD-1/PD-L1 com-
pared to PD-L1-blocking antibody MEDI4736. However, upon
binding to EGFR-overexpressing target cells the PD-L1-block-
ing capacity of PD-L1xEGFR was restored to that of
MEDI4736. Compared to indiscriminate high-afﬁnity PD-L1-
binding activity by MEDI4736, the EGFR-dependent PD-L1-
blocking capacity of PD-L1xEGFR may be beneﬁcial to reduce
‘on-target/off-tumor’ effects.
Our results indicate that PD-L1xEGFR enhances activation
of antigen-experienced T cells in an EGFR-directed manner. In
particular, treatment of CMV-pp65 transfected EGFRC cancer
cells with PD-L1xEGFR, followed by removal of unbound anti-
body, promoted the activity of HLA-matched CMV-speciﬁc
CD8C T cells which was corroborated by increased expression
of CD137, CD107a, granzyme B, and IFN-g production. Previ-
ously, it was reported that PD-L1-blocking antibody avelumab
Figure 3. PD-L1xEGFR promotes cytotoxic activity of BIS-1-redirected T cells (A) FaDu cells were mixed with T cells at E:T ratio of 2:1 in the presence of BIS-1 (75 ng/ml)
and 5 mg/ml PD-L1xEGFR or control antibodies. (B) A431 cells were treated as described in (A). Apoptosis was determined in A and B at day 3 by ﬂow cytometry using
Annexin-V staining. Apoptosis for isotype control treatments were subtracted. (C) IFN-g levels in culture supernatant of (A) were determined by ELISA and IFN-g levels for
isotype control treatment were subtracted. (D) A431 cells were treated with the indicated antibodies, washed to remove unbound antibody and then mixed with T cells
at an E:T ratio of 2:1 in the presence of BIS-1 (75 ng/ml). At day 3, T cells were carefully removed by washing, after which light microscopic images of the remaining A431
monolayer were evaluated. (E) In mixed cultures with EGFRC FaDu and A431 or EGFR¡ A2058.EpCAM cells as described in D, apoptosis was determined by ﬂow cytometry
using Annexin-V staining. Apoptosis for isotype control treatments were subtracted. (F) In mixed cultures with FaDu cells as described in D, expression of T cell activation
mrker CD25 was analyzed by ﬂow cytometry. Mean ﬂuorescence intensity (MFI) of BIS-1 treatment alone was subtracted. Three independent experiments were performed
and represent mean § SD. Statistical analysis was performed using One-way ANOVA followed by a Bonferroni post-hoc test ( p < 0.05,  p < 0.01,  p < 0.001, ns not
signiﬁcant).
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has similar in vitro capacity to enhance activation of antigen-
experienced T cells directed against CMV, EBV, Flu or teta-
nus,27 albeit obviously not in a tumor-directed manner.
Typically, PD-1/PD-L1-blocking antibodies are engineered
as human IgG4 or to have reduced or silenced ADCC activity
to avoid elimination of PD-1/PD-L1-expressing immune
cells.28,29 However, human IgG1 containing avelumab was
shown to have a toxicity proﬁle comparable to ADCC-null PD-
L1-blocking antibodies30-32 with low levels of lysis of PBMCs in
vitro.27,33 Moreover, NK cell-mediated ADCC by avelumab was
shown to enhance its therapeutic functionality.33,34 Similarly,
the human IgG1 domain present in PD-L1xEGFR may enhance
its therapeutic activity as it promotes NK cell-mediated ADCC
towards EGFR-expressing cancer cells.
Collectively, our data demonstrates that PD-L1xEGFR has
multiple mutually reinforcing anticancer activities not available
in any of the current conventional PD-L1-blocking antibodies.
In particular, PD-L1xEGFR: 1. simultaneously binds to both
PD-L1 and EGFR resulting in enhanced avidity towards PD-
L1C/EGFRC cancer cells; 2. blocks oncogenic EGFR-signaling
which sensitizes cancer cells to therapy; 3. blocks PD-1/PD-L1
interaction in an EGFR-directed manner; 4. promotes antican-
cer activity of both anti-CD3xanti-EpCAM-redirected and anti-
gen-experienced T cells in an EGFR-directed manner; 5.
induces elimination of EGFRC tumor cells by NK cell-mediated
ADCC; 6. accumulates more selectively in EGFRC xenografts.
Taken together, our PD-L1xEGFR-based approach may rep-
resent a next step towards enhancing selectivity, efﬁcacy and
safety of PD-1/PD-L1 checkpoint inhibition approaches in




Goat anti-human Ig-PE (Southern Biotech), anti-PD-L1-APC
(clone 29E.2A3, BioLegend), anti-EGFR-FITC (clone 528, Santa
Figure 4. PD-L1xEGFR enhances cytotoxic potential of antigen-experienced T cells A431 or A431.pp65 cells were treated with PD-L1xEGFR or control antibodies, after
which unbound antibody was washed away. Subsequently, T cells derived from CMV-seropositive donors were added at an E:T ratio of 20:1. After 8 days, expression levels
of indicated activation markers were measured. (A) HLA-DR and CD25 expression, representative of 3 independent experiments. (B) CD137 expression, representative of 3
independent experiments. (C) CD137, CD107a (D) and intracellular IFN-g (E) expression levels were analyzed within CD8C T cell population by ﬂow cytometry. (F) Gran-
zyme B levels present in culture supernatants of treatment conditions as described in A were determined by ELISA.
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Cruz Biotechnology), anti-CD107a-APC (clone H4A3, BD Phar-
mingen), anti-CD137-PE (clone 4B4), anti-IFN-g-PerCP-Cya-
nine5.5 (clone 4S.B3,), anti-CD3-PerCP-Cyanine5.5 (clone
OKT-3, all from eBioscience), and anti-CD3-FITC
(clone Ucht1), anti-CD8-FITC, APC (clone HIT8a), anti-CD56-
PE (clone B-A19), anti-CD14-FITC, PE (clone MEM-15), anti-
CD25-FITC, APC (clone MEM-181), anti-HLA-DR-FITC, PE
(clone MEM-12), mouse IgG1-FITC, PE, Mouse IgG2b-APC,
Annexin-V-FITC (all from Immunotools). Recombinant human
IFN-g, TNF-a, PGE2, GM-CSF, IL-1b, IL-4, IL-6, IL12 and
anti-CD3 mAb UCHT-1 were from Immunotools. PD-L1-block-
ing mAb was from BPS Bioscience. Anti-EGFR mAb 425 was
from Merck. Cetuximab was obtained from the Department of
Hospital Pharmacy, UMCG, The Netherlands. Secretion of cyto-
kines by T cells was measured using appropriate ELISA kits
(IFN-g from eBioscience and granzyme B from Mabtech).
Cell lines and transfectants
Cell lines A431, FaDu, H292, OVCAR3, HT1080, DLD-1,
SK-BR-3, LNCaP, A2058, A375 m, A2780, CHO-K1 and
Jurkat cells were obtained from the American Type Culture
Collection (ATCC). Cells were cultured in RPMI-1640 or
DMEM (Lonza), supplemented with 10% fetal calf serum
(FCS, Thermo Scientiﬁc), CHO-K1 cells were cultured in
GMEM (First Link), supplemented with 5% dialyzed FBS
(Sigma Aldrich) at 37C in a humidiﬁed 5% CO2 atmo-
sphere. Cell line authentication was carried out by short tan-
dem repeat (STR) analysis. CHO.PD-L1 cells stably
expressing human PD-L1 were generated by lipofection
(Fugene-HD, Promega) with plasmid pCMV6-PD-L1 (Ori-
gene). A431.pp65 cells stably expressing cytomegalovirus
(CMV) protein pp65 were generated by lipofection with
plasmid pCMV6-pp65 (Origene). A2058.EpCAM cells stably
expressing EpCAM-YFP were generated by lipofection with
plasmid pEpCAM-YFP-N1 (kindly provided by Dr. Olivier
Gires, Munich, Germany). Clones with stable expression of
the indicated transgenes were selected using culture media
supplemented with the appropriate antibiotic. PD-L1, EGFR
and EpCAM expression was analyzed for all cell lines by
ﬂow cytometry using anti-PD-L1-APC, anti-EGFR-FITC and
anti-EpCAM-FITC antibodies and appropriate isotype con-
trols. The relative expression levels of PD-L1, EGFR and
EpCAM are listed in Supplementary Table 1.
Figure 5. PD-L1xEGFR induces NK-cell mediated ADCC (A) FaDu cells were mixed with IL-12-pre-treated NK cells at the indicated E:T ratios and in the presence of 5 mg/ml
PD-L1xEGFR or control antibodies. (B) FaDu cells were co-cultured with IL-12-pretreated NK cells at an E:T ratio of 2:1 as described in A. (C) LNCaP cells were mixed with
PBMCs at an E:T ratio of 5:1 in the presence of 5 mg/ml PD-L1xEGFR or control antibodies. In all experiments apoptosis was determined by ﬂow cytometry using Annexin-
V staining procedure. All graphs represent mean § SD. Statistical analysis in B and C were performed using One-way ANOVA followed by a Bonferroni post-hoc test (p
< 0.05,  p < 0.01,  p < 0.001, ns not signiﬁcant).
Figure 6. Biodistribution of radiolabeled 111In-PD-L1xEGFR. (A) Binding of 111In-PD-
L1xEGFR or 111In-PD-L1xMock to PD-L1 and EGFR in the presence or absence of
excess MEDI4736 and/or EGFR blocking mAb 425 on A431 and (B) SK-BR-3 cells.
(C) Tumor uptake of 111In-PD-L1xEGFR (1 mg) in mice with subcutaneous A431
(n D 5) or SK-BR-3 (n D 5) xenografts. Separate groups of mice were injected with
control antibody 111In-PD-L1xMock. Tumor uptake was calculated as % injected
dose per gram tissue (%ID/g) (D) Tumor-to-blood ratio was calculated, from experi-
ment as described in C. Statistical analysis in D was performed using One-way
ANOVA followed by a Bonferroni post-hoc test ( p < 0.05,  p < 0.01,  p <
0.001, ns not signiﬁcant).
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Construction of PD-L1xEGFR
DNA fragments encoding scFvPD-L1 and scFv425 were gener-
ated by commercial gene synthesis service (Genscript) based on
published VH and VL sequence data of PD-L1-blocking anti-
body 3G10 and EGFR-directed antibody mAb 425, respectively.
For construction and production of PD-L1xEGFR we used
eukaryotic expression plasmid pEE14-bsAb,35 which contains 3
consecutive multiple cloning sites (MCS). MCS#1 and MCS#2
are interspersed by a 22 amino acid ﬂexible linker derived from
a CH1 IgG domain.36 MCS#1, MCS#2 and MCS#3 were used
for directional and in-frame insertion of DNA fragments
encoding scFvPD-L1, scFv425, and human IgG1 Fc domain,
respectively, yielding plasmid pEE14-PD-L1xEGFR (Suppl.
Fig. 1A and B). Of note, pEE14 is equipped with a strong CMV
promotor and a murine kappa light-chain leader peptide for
driving expression of PD-L1xEGFR through the ER and Golgi
complex ensuring excretion of correctly folded and biological
active recombinant protein with authentic port-translational
modiﬁcations. A human IgG1 hinge region and G4S spacers
between antigen recognizing domains were applied to promote
ﬂexibility of bsAb PD-L1xEGFR (Suppl. Fig. 1C). Analogously,
pEE14-PD-L1xMock encoding PD-L1xMock was constructed
by replacing scFv425 in pEE14-PD-L1xEGFR by scFv4-4-20
directed against ﬂuorescein.
Eukaryotic production of bsAbs
PD-L1xEGFR and PD-L1xMock were produced using the
Expi293 expression system (ThermoFisher). Brieﬂy, Expi293
cells were transfected with plasmid pEE14-PD-L1xEGFR or
pEE14-PD-L1xMock and cultured for 7 days on a shaker plat-
form (125 rpm) at 37C, 8% CO2. Next, culture supernatant
was harvested and cleared by centrifugation (3000 x g, 30 min),
after which PD-L1xEGFR and PD-L1xMock were puriﬁed
using an HiTrap protein A HP column connected to an €AKTA
Start chromatography system (GE Healthcare Life Sciences).
SDS-PAGE analysis of PD-L1xEGFR
Protein A-puriﬁed PD-L1xEGFR or MEDI4736 (2,5 mg) were
separated by SDS-PAGE (10% acrylamide) under reducing
(with b-mercaptoethanol) or nonreducing conditions (without
b-mercaptoethanol), followed by staining of the gel with Coo-
massie Brilliant Blue. Under nonreducing conditions PD-
L1xEGFR migrated as a single protein band with an apparent
molecular weight of 170 kDa, which dropped to 80 kDa when
separated under reducing conditions. This is in good agreement
with the calculated molecular weight of 84 kDa for PD-
L1xEGFR monomer and the proposed disulﬁde-stabilized
dimeric single chain composition of the native protein.
MEDI4736 showed the expected heterodimeric composition of
heavy and light chain characteristic for conventional antibodies
(Suppl. Fig. 1D).
Binding activity of PD-L1xEGFR for PD-L1 and EGFR
Flow cytometry was used to evaluate the binding activity of PD-
L1xEGFR for PD-L1 and EGFR using a broad panel of cell lines
(CHO, CHO.PD-L1, EGFRC cancer cell lines A431, FaDu,
OVCAR3, HT1080, DLD1, LNCaP and EGFR¡ cancer cell lines
A2058, A375 m, A2780, Jurkat). In short, cells were incubated
with increasing amounts of PD-L1xEGFR (0.01–10 mg/ml,
45 min at 4C), washed 3 times with PBS, and then incubated
with anti-human-Ig-PE mAb (45 min at 4C) and evaluated by
ﬂow cytometry. Binding for PD-L1xEGFR (1 mg/ml) to A431
cells was blocked by either PD-L1-blocking mAb (10 mg/ml),
mAb 425 (10 mg/ml), or a combination of PD-L1-blocking
mAb and mAb 425.
Competitive binding assay
Overall binding strength (avidity) of PD-L1xEGFR and PD-
L1xMock, for PD-L1C/EGFRC cancer cells was compared in a
competitive binding assay, essentially as described previously.37
In short, A431 cells were pre-incubated (or not) with excess
amounts of mAb 425 (50 mg/ml) for 15 min at 4C, after which
PD-L1xEGFR or PD-L1xMock was added in a concentration
range from 0.01 to 50 mg/ml, in the presence of an APC-labeled
PD-L1-blocking mAb (8 mg/ml). After 45 min the tumor cell-
bound APC levels were quantiﬁed by ﬂow cytometry. Of note,
in this assay, the binding capacity of the tested bispeciﬁc anti-
body is inversely proportional to its capacity to reduce binding
of the APC-labeled PD-L1-blocking antibody.
Bioassay for PD-1/PD-L1 blockade
Blockade of PD-1/PD-L1 interaction was assessed using a com-
mercially available PD-1/PD-L1 Blockade Bioassay (Promega).
This assay exploits Jurkat.PD1-NFAT-luc T cells (expressing
PD-1 and NFAT-inducible luciferase) and CHO-PD-L1-CD3
cells (expressing PD-L1 and a membrane-linked agonistic anti-
CD3 antibody). When co-cultured, PD-1/PD-L1 interaction
between both cell types inhibits TCR signaling and NFAT-
mediated luciferase activity in Jurkat.PD1-NFAT-luc T cells.
Addition of a PD-1/PD-L1 blocking agent, such as PD-
LxEGFR, PD-L1xMock and MEDI4736, results in releasing
PD-1/PD-L1 block on NFAT-mediated luciferase activity in
Jurkat.PD1-NFAT-luc T cells.
Bioassay for EGFR-directed PD-1/PD-L1 blockade
by PD-L1xEGFR
The capacity of PD-L1xEGFR for EGFR-directed PD-1/PD-L1
blockade was assessed using a modiﬁed version of the above
PD-1/PD-L1 Blockade Bioassay by replacing CHO.PD-L1/CD3
cells by A431 cells that were pretreated with a suboptimal
amount of BIS-1. BIS is an EpCAM-directed CD3-agonistic
bsAb.38 This modiﬁcation allows for redirecting the Jurkat.
PD1-NFAT-luc T cells towards EpCAMC A431 carcinoma
cells. In short, Jurkat.PD1-NFAT-luc T cells were mixed BIS-1-
pretreated A431 cells at a cell ratio of 5 to 1 and then cultured
for 18 h in the presence of PD-L1xEGFR or appropriate control
antibodies. Subsequently, Bio-Glo reagent was added after
which bioluminescence was quantiﬁed using a Victor V3 multi-
label plate reader (Perkin Elmer).
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Inhibition of EGFR-mediated cancer cell proliferation
by PD-L1xEGFR
FaDu and H292 cancer cells were pre-cultured in 48-wells
plates for 6 h at 8.000 cells/well, followed by addition of PD-
L1xEGFR, PD-L1xMock or appropriate control antibodies
(each 5 mg/ml). After 5 days, cancer cell proliferation was
determined in an MTS-based colorimetric assay (CellTiter 96,
Promega) using a Victor V3 multi-label plate counter at
490 nm. Absorbance data for maximum cell death were
obtained by control treatment with 70% ethanol for 15 min.
Activation BIS-1-redirected T cells by PD-L1xEGFR
T cells were sorted from PBMCs by MACS (human Pan T cell
isolation kit, Miltenyi Biotec). T cells were incubated with a
suboptimal amount of bsAb BIS-1 (75 ng/ml) and then added
to A431, FaDu or A2058.EpCAM target cells in an E:T ratio of
2 to 1, in the presence or absence of PD-L1xEGFR, appropriate
control antibodies (each 5 mg/ml), geﬁtinib, erlotinib (10 nM/
ml) or DMSO control. At day 3, apoptosis induction in cancer
cells (Annexin-V) and CD25 expression on T cells were evalu-
ated by ﬂow cytometry.
Activation of CMV-speciﬁc T cells by PD-L1xEGFR
A431.CMVpp65 or wild-type (wt) A431 cells were incubated
with PD-L1xEGFR or appropriate control antibodies (5 mg/
ml), washed to remove unbound antibody and then cultured
in 48-wells plates (3 £ 104 cells/well). Freshly isolated PBMCs
from a healthy CMVC donor were added to cancer cells at an
E:T ratio of 20 to 1. After 4 days, the various experimental
conditions were restimulated by adding fresh A431.pp65 or wt
A431 cells. At day 7, »50% of PBMCs of the various condi-
tions was used for restimulation with A431.pp65 or wt A431
cancer cells overnight. At day 8, the cytotoxic potential of
CMV-speciﬁc CD8C T cells was assessed by measurement of
degranulation marker CD107a (FastImmune CD107a APC
reagent, BD Pharmingen) and intracellular IFN-g (FIX&-
PERM, Nordic-MUbio and anti-IFN-g-PerCP-Cyanine5.5).
The remaining 50% of the CD3C/CD8C T cells was used for
evaluation of cell surface expression of HLA-DR, CD25 and
CD137 by ﬂow cytometry. Supernatant was used for granzyme
B ELISA.
NK cell-mediated ADCC by PD-L1xEGFR
Natural killer (NK) cells were sorted from PBMCs using the
MagnisortTM Negative Selection kit (eBioscience). Sorted NK
cells (1 £ 106 cells/ml) were stimulated using in RPMI-1640/
FBS medium supplemented with IL-12 (10 ng/ml) for 24 h as
described previously.33 NK cells were washed with PBS and
then mixed with cancer cells at the indicated E to T ratios and
treated with PD-L1xEGFR, PD-L1xMock or appropriate con-
trol antibodies (each 5 mg/ml). After 18 h of treatment, apo-
ptosis was assessed by ﬂow cytometry using Annexin-V
staining.
Alternatively, LNCaP cells were co-cultured with PBMCs at
an E to T cell ratio of 5 to 1 and then treated with PD-
L1xEGFR or indicated control antibodies (each 5 mg/ml).
After 48 h, ADCC-mediated apoptosis induction in cancer
cells was assessed by ﬂow cytometry using Annexin-V staining
procedure.
Radiolabeling and in vitro binding of 111In-PD-L1xEGFR
and 111In-PD-L1xMock
BsAbs PD-L1xEGFR and PD-L1xMock were conjugated with
isothiocyanatobenzyl- diethylenetriaminepentaacetic acid
(ITC-DTPA, Macro Cyclics) and radiolabeled with 111In as
described previously.39 To assess binding of radiolabeled bsAbs
to PD-L1 and EGFR, A431 and SK-Br-3 cells were incubated
for 4 h at 37C with 21.6 pM 111In-PD-L1xEGFR or 111In-PD-
L1xmock. To show binding speciﬁcity for PD-L1 and EGFR,
separate wells were incubated with 66 nM non-labeled mAb
425 or MEDI4736. After incubation, cells were lysed using
0.1 M NaOH and cell-associated activity was measured in a
shielded well-type gamma counter (Perkin-Elmer, Boston, MA,
USA).
Biodistribution in tumor-bearing nude mice
Animal studies were performed using 6–8 weeks old female
BALB/c nude mice (Janvier, France) in accordance with the
Dutch Act on Animal Experimentation and approved by the
institutional Animal Welfare Committee at Radboud Univer-
sity Nijmegen. To determine blood kinetics, two groups of 5
non-tumor bearing mice were injected with 5 mg (0.2 MBq)
111In-PD-L1xEGFR or 111In-PD-L1xmock. Blood samples were
obtained at 5 min, 1 h, 4 h, 6 h, 24 h, 48 h and 72 h, and 168
post injection. To compare the tumor targeting properties of
the bsAbs, two groups of 10 mice were injected subcutaneously
on the right ﬂank with either 5 £ 106 SK-BR-3 cells, represent-
ing an EGFRlow low expression pattern (n D 10) in 33% Matri-
gel matrix (Corning) RPMI 1640 or 3 £ 106 A431 cells,
representing an EGFRhigh expression pattern (n D 10) in RPMI
1640. After ten days, mice were injected in the tail vein with
1 mg 111In-PD-L1xEGFR or 111In-PD-L1xMock (0.2 MBq, n D
5 per group). Three days post injection, mice were euthanized
using CO2/O2-asphyxation. The biodistrubution of radiolabel
was determined ex vivo. Tumor, blood, muscle, lung, spleen,
pancreas, intestine, kidney, liver, bone, bone marrow and
lymph nodes were excised and weighed and evaluated in a
gamma counter. To determine the uptake of radiolabeled anti-
bodies in each sample as a fraction of the injected dose, aliquots
of the injected dose were counted simultaneously. Results were
decay corrected and expressed as percentage injected dose per
gram tissue (%ID/g).
Statistical analysis
IC50 values were determined by nonlinear regression analysis of
concentration response curves using GraphPad Prism. Unless
otherwise noted, values are mean § SD. Statistical analysis was
done by one-way ANOVA followed by Bonferroni post-hoc
test, as indicated using Prism software. P<0.05 was deﬁned as a
statistically signiﬁcant difference. Where indicated  D P<0.05;
 D P<0.01;  D P<0.001.
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